|
Volumn 95, Issue 17, 2003, Pages 1273-1274
|
Clinical trials test bisphosphonates in hormone-sensitive prostate cancer
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANDROGEN;
BISPHOSPHONIC ACID DERIVATIVE;
CLODRONIC ACID;
PLACEBO;
ZOLEDRONIC ACID;
ANTIANDROGEN;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
IMIDAZOLE DERIVATIVE;
ANTINEOPLASTIC ACTIVITY;
BONE DEFECT;
BONE DISEASE;
BONE METASTASIS;
CANCER HORMONE THERAPY;
CANCER LOCALIZATION;
CANCER STAGING;
CLINICAL TRIAL;
HORMONE SENSITIVITY;
HUMAN;
NOTE;
OSTEOLYSIS;
OSTEOPOROSIS;
PRIORITY JOURNAL;
PROSTATE CANCER;
TREATMENT OUTCOME;
BONE TUMOR;
CHEMICALLY INDUCED DISORDER;
CONTROLLED CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
MALE;
METASTASIS;
MULTICENTER STUDY;
NEOPLASM;
PATHOLOGY;
PROSTATE TUMOR;
RANDOMIZED CONTROLLED TRIAL;
TIME;
ANDROGEN ANTAGONISTS;
ANTINEOPLASTIC AGENTS, HORMONAL;
BONE NEOPLASMS;
CLODRONIC ACID;
DIPHOSPHONATES;
DISEASE-FREE SURVIVAL;
HUMANS;
IMIDAZOLES;
MALE;
MULTICENTER STUDIES;
NEOPLASM STAGING;
NEOPLASMS, HORMONE-DEPENDENT;
OSTEOPOROSIS;
PROSTATIC NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS;
TIME FACTORS;
TREATMENT OUTCOME;
|
EID: 0041830479
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/95.17.1273 Document Type: Note |
Times cited : (1)
|
References (0)
|